Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Aneesha DasguptaDepartment of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0001-7479-1149
Rebecca E SchmittDepartment of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0003-3029-8023
Tatsuyoshi KonoDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-7524-6836
Chih-Chun LeeDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0003-2802-519X
Mark I ZoberiIndiana University Simon Comprehensive Cancer Center , Indianapolis, IN, USA.ORCID 0009-0009-1397-9581
Savannah A EpsteinDepartment of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0003-1910-5024
Alejandro HernandezDepartment of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-0895-6811
Paul M GrandgenettFred & Pamela Buffett Cancer Center, University of Nebraska Medical Center , Omaha, NE, USA.ORCID 0000-0002-6905-1805
Thomas C CaffreyEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center , Omaha, NE, USA.ORCID 0000-0001-6707-8468
Dominick J DiMaioDepartment of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0001-6773-5587
Michael A HollingsworthFred & Pamela Buffett Cancer Center, University of Nebraska Medical Center , Omaha, NE, USA.ORCID 0000-0002-5255-8888
Jason D DolesDepartment of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-6830-708X
Funding
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2015 to 2026
$17.4M
Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
National Metabolomics Data Repository - nextgen Metabolomics WorkbenchU2CDK119886 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2018 to 2021
$12.7M
Biomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2020 to 2024
$3.2M
Critical Resources Provided by UNMC Rapid Autopsy Program (RAP) Biorepository Stimulate Cancer ResearchR50CA211462 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Paul M Grandgenett · 2016 to 2026
$1.4M
Targeting Perp in PDAC tumor and cancer cachexiaK99CA283277 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI DASGUPTA, ANEESHA · 2024 to 2025
$262k
American Association for Cancer ResearchIndiana UniversityMayo ClinicNational Cancer Institute Cancer Center P30CA36727NCI NIH HHS K99 CA283277NCI NIH HHS P30 CA036727NCI NIH HHS R50 CA211462NCI NIH HHS R50CA211462NCI NIH HHS U01 CA210240NIDDK NIH HHS P30 DK097512NIDDK NIH HHS U2C DK119886NIH HHS K99CA283277NIH HHS OT2 OD030544NIH HHS OT2-OD030544NIH HHS P30DK097512NIH HHS U2C-DK119886Pancreatic Cancer Action NetworkPancreatic Cancer Detection Consortium U01CA210240
6 · The paper itself
Abstract
Cancer cachexia is a multifactorial syndrome involving muscle and fat wasting, inflammation, and metabolic dysfunction. Across cancer subtypes, pancreatic cancer has one of the highest cachexia incidence rates at ∼80%. Given the advanced age of most pancreatic cancer patients, we sought to query cancer-associated muscle wasting using an age-matched murine model. We found that histamine and histamine decarboxylase (HDC) activity were specifically elevated in the muscles of aged tumor-bearing mice. We further found that (1) wasting stimuli induced histamine production and enhanced HDC activity; (2) exogenous histamine was sufficient to induce atrophy-associated gene expression; (3) inhibition of HDC activity by α-fluoromethylhistidine (FMH) protected against atrophy; (4) treatment of tumor-bearing mice with FMH rescued muscle wasting; and (5) a calcineurin inhibitor was able to rescue histamine-associated increases in calcium/atrogene signaling. In summary, we present a novel metabolic pathway that has significant implications for the treatment of cachectic cancer patients.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Histidine decarboxylase inhibition attenuates cancer-associated muscle wasting. · full record | OpenQuestion